Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced its participation in the 41^st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA. The company's management will present their innovative treatments aimed at serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. A live webcast of the presentation will be accessible on their investor relations website, with an archived replay available afterward.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41^st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated bivalent Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes. Akero is headquartered in South San Francisco. Visit akerotx.com and follow us on LinkedIn and Twitter for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
Sarah O’Connell
732.456.0092
soconnell@vergescientific.com

FAQ

When will Akero Therapeutics present at the J.P. Morgan Healthcare Conference?

Akero Therapeutics will present on January 10, 2023, at 10:30 a.m. P.T.

Where can I watch the Akero Therapeutics presentation?

The presentation will be available via a live webcast on Akero's investor relations website.

What is Akero Therapeutics focusing on at the conference?

Akero is focusing on their treatments for serious metabolic diseases, especially non-alcoholic steatohepatitis (NASH).

What are the key products being discussed by Akero at the conference?

Akero's lead product candidate is efruxifermin (EFX), aimed at treating NASH.

What is the significance of the efruxifermin (EFX) product?

EFX is designed to be a best-in-class treatment for NASH, with convenient once-weekly dosing.

What clinical trials is Akero currently conducting?

Akero is conducting two Phase 2b clinical trials, the HARMONY study and the SYMMETRY study, for efruxifermin.